Codexis, Inc.（CDXS）资讯与事件CDXSCodexis, Inc.

Codexis Partners with siRNA Innovator for Fragment Synthesis

Codexis announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis. Under the agreement, Codexis will use its ECO Synthesis platform to produce stereo-defined oligonucleotide fragments through a fully enzymatic process. The fragments will be supplied to the innovator to assemble into the final duplex via ligation, an approach that is gaining momentum as a next-generation manufacturing paradigm for oligonucleotides due to its potential to enhance scalability, efficiency, and product quality. The collaboration will also compare enzymatically synthesized fragments with conventional solid-phase oligonucleotide synthesis, evaluating purity, product quality, and ligation performance. The results will allow the innovator to assess the technology's potential for future clinical development programs.

Codexis Expects Cash to Fund Operations Through 2028

The company said, "Codexis expects that its existing cash, cash equivalents, and short-term investments will be sufficient to fund its planned operations through the end of 2028. The financial guidance and cash runway projections include the expenses associated with the build out of the GMP production facility."

Codexis Reports Q2 Revenue of $14.92M, Beating Consensus

Reports Q2 revenue $14.92M, consensus $13.82M. "I am pleased with the strong financial results reported today for the second quarter of 2026," stated Alison Moore, President and Chief Executive Officer of Codexis. "In May, we presented new data at the TIDES US annual meeting demonstrating how the ECO Synthesis Manufacturing Platform enables control over stereochemistry in the manufacture of siRNA compounds which may enhance their potency and product quality. We also demonstrated our technology has the ability to initiate enzymatic RNA synthesis starting from a single nucleotide. In addition, our balance sheet was significantly strengthened by a capital raise of approximately $25 million in net proceeds, completed in July. We have made significant progress in the first half of 2026 in industrializing our ECO Synthesis Manufacturing Platform, and look forward to continued demonstration of the value of our technology to our customers in the second half."